These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 338900)

  • 81. Structure of two hydroxylated metabolites of ftorafur.
    Meyer RB; Levenson CH
    Biochem Pharmacol; 1980 Feb; 29(4):665-8. PubMed ID: 6768366
    [No Abstract]   [Full Text] [Related]  

  • 82. [Mechanism of the chromosome damaging effect of ftorafur].
    Volgareva GM; Sokova OI; Pogosiants EE
    Genetika; 1977; 13(3):461-7. PubMed ID: 142687
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Clinical experiences with UFD-1].
    Furue H
    Gan To Kagaku Ryoho; 1982 Apr; 9(4):672-4. PubMed ID: 6820905
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Conversion of 1-(2-tetrahydrofuryl-5-fluorouracil (FT-207) into 5-fluorouracil (5-FU) by human maxillary cancer cells (OKK) in culture].
    Yoneda T; Ogawa T; Sakuda M
    Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1207-8. PubMed ID: 6409001
    [No Abstract]   [Full Text] [Related]  

  • 85. Comparative studies on the immunosuppressive effect among 5'-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil.
    Ohta Y; Sueki K; Kitta K; Takemoto K; Ishitsuka H; Yagi Y
    Gan; 1980 Apr; 71(2):190-6. PubMed ID: 6451468
    [TBL] [Abstract][Full Text] [Related]  

  • 86. In vitro biological evaluation of the R and S isomers of 1-(Tetrahydrofuran-2-yl)-5-fluorouracil.
    Horwitz JP; McCormick JJ; Philips KD; Maher VM; Otto JR; Kessel D; Zemlicka J
    Cancer Res; 1975 May; 35(5):1301-4. PubMed ID: 1168096
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Tissue distribution of 5'-deoxy-5-fluorouridine and derived 5-fluorouracil in tumor-bearing mice and rats.
    Suzuki S; Hongu Y; Fukazawa H; Ichihara S; Shimizu H
    Gan; 1980 Apr; 71(2):238-45. PubMed ID: 6451469
    [TBL] [Abstract][Full Text] [Related]  

  • 88. General pharmacological properties of UFT, a new type of anti-cancer agent consisting of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) and uracil. I: Pharmacological analysis of the combined effect of FT and uracil.
    Yamamoto J; Toide K; Haruno A; Yoshimura Y; Unemi N
    Arzneimittelforschung; 1981; 31(8):1268-78. PubMed ID: 6794578
    [TBL] [Abstract][Full Text] [Related]  

  • 89. [Gene mutation induction by the antitumor preparation ftorafur].
    Volgareva GM; Stavrovskaia AA; Pogosiants EE
    Genetika; 1982 May; 18(5):758-63. PubMed ID: 6807754
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The metabolism of ftorafur in the beagle dog and rhesus monkey.
    Freudenthal RI; Emmerling DC
    Xenobiotica; 1977 Dec; 7(12):757-64. PubMed ID: 414463
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Optical isomers of 2-(2-ethoxyphenoxymethyl)tetrahydro-1,4-oxazine (viloxazine) and related compounds.
    Howe R; Leigh T; Rao BS; Todd AH
    J Med Chem; 1976 Aug; 19(8):1074. PubMed ID: 966254
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effect of L-cysteine on distribution volume of 1-(tetrahydro-2-furanyl)-5-fluorouracil.
    Kawabata N; Yano K; Ohno H; Nakashima T
    Jpn J Pharmacol; 1990 Dec; 54(4):487-90. PubMed ID: 2087012
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Improved chemical syntheses of 5,6-dihydro-5-fluorouracil.
    LaFrate AL; Katzenellenbogen JA
    J Org Chem; 2007 Oct; 72(22):8573-6. PubMed ID: 17900141
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Evolution of molecular combinations involving 5-fluorouracil.
    McElhinney RS; McCormick JE; Lucey CM
    Cancer Treat Rev; 1988 Mar; 15(1):73-81. PubMed ID: 3359452
    [No Abstract]   [Full Text] [Related]  

  • 95. [Phenyltyramines right, left and racemic; Comparative physicochemical and pharmacological properties of the three isomers].
    CHEYMOL J; LESPAGNOL A
    C R Hebd Seances Acad Sci; 1947 May; 224(19):1385. PubMed ID: 20256095
    [No Abstract]   [Full Text] [Related]  

  • 96. Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma.
    Kawata S; Noda S; Imai Y; Tamura S; Saitoh R; Miyoshi S; Minami Y; Tarui S
    Gastroenterol Jpn; 1987 Feb; 22(1):55-62. PubMed ID: 3032726
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
    Yasumoto M; Moriyama A; Unemi N; Hashimoto S; Suzue T
    J Med Chem; 1977 Dec; 20(12):1592-4. PubMed ID: 338900
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
    Yasumoto M; Yamawaki I; Marunaka T; Hashimoto S
    J Med Chem; 1978 Aug; 21(8):738-41. PubMed ID: 357721
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Stereoselective metabolism of ftorafur (R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil).
    Au JL; Sadée W
    Cancer Chemother Pharmacol; 1981; 7(1):55-9. PubMed ID: 6804104
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.